An Israeli study released on Saturday found that the coronavirus variant first detected in South Africa is able to “break through” the antibodies created from …
An Israeli study released on Saturday found that the coronavirus variant first detected in South Africa is able to “break through” the antibodies created from the Pfizer-BioNTech vaccine to some extent. The study was carried out by Tel Aviv University and Israel’s largest health care provider Clalit, Reuters reported. The study compared around 400 people who tested positive for COVID-19 after receiving one or more doses of the Pfizer vaccine to the same number of unvaccinated people who had also tested positive. The outlet noted that Israel does not have a high prevalence of the South African variant and that the research has not been peer reviewed.
